Tolerability and compliance with risedronate in clinical practice
- 1 March 2003
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 14 (3) , 259-262
- https://doi.org/10.1007/s00198-002-1370-3
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Upper Gastrointestinal Tract Safety of Risedronate: A Pooled Analysis of 9 Clinical TrialsMayo Clinic Proceedings, 2002
- Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid-Induced Osteoporosis in Men and Women: A Randomized TrialJournal of Bone and Mineral Research, 2000
- Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.2000
- Therapeutic equivalence of alendronate 70 mg onceweekly and alendronate 10 mg daily in the treatment of osteoporosisAging Clinical and Experimental Research, 2000
- Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal OsteoporosisOsteoporosis International, 2000
- Risedronate therapy prevents corticosteroid-induced bone loss : A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyArthritis & Rheumatism, 1999
- Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled TrialJAMA, 1999
- Alendronate Use Among 812 Women: Prevalence of Gastrointestinal Complaints, Noncompliance with Patient Instructions, and DiscontinuationJournal of Managed Care Pharmacy, 1998
- Incidence of gastrointestinal side effects due to alendronate is high in clinical practiceBMJ, 1997
- Esophagitis Associated with the Use of AlendronateNew England Journal of Medicine, 1996